Doç. Dr. Özlem Nuray SEVER

1. Prognostic role of smoking in metastatic renal cell carcinoma in real-world data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

Bolek H., Sertesen Camoz E., Kuzu O. F., Karakas H., Sim S., Sekmek S., et al.

Scientific Reports , cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)

2. Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study

Günaltılı M., Bölek H., Kaplan Tüzün E., Usta S., Efil S. C., AKKUŞ A. F., et al.

Cancers , cilt.18, sa.13, 2026 (SCI-Expanded, Scopus)

3. Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors

Gürbüz M., Tural D., ÇİL T., Demir H., KÖSTEK O., SEVER Ö. N., et al.

JCO Global Oncology , cilt.12, 2026 (ESCI, Scopus)

4. Optimizing Antiemetic Strategies Across Phases of Chemotherapy-Induced Nausea and Vomiting: Real-World Evidence in Breast Cancer

Doğan A., Erölmez H. N., Akdağ G., Yıldırım S., SEVER Ö. N.

Current Oncology , cilt.33, sa.2, 2026 (SCI-Expanded, Scopus)

5. Prognostic Value of the Cancer Inflammation Prognostic Index (CIPI) in De Novo Metastatic Colon Cancer: A Multicenter Retrospective Cohort Study

Doğan A., Yıldırım S., Erölmez H. N., Akdağ G., Yıldız H. Ş., Yüksel Yaşar Z., et al.

Cancer Control , cilt.33, 2026 (SCI-Expanded, Scopus)

6. Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study

Yildirim S., SEVER Ö. N., Turkoglu E., Sariyar Busery N., Dogan A., Baydas T., et al.

Clinical Medicine Insights: Oncology , cilt.20, 2026 (SCI-Expanded, Scopus)

7. Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma

Kuzu O. F., Bolek H., Sertesen Camoz E., Karakas H., Sekmek S., Sim S., et al.

BMC Cancer , cilt.25, sa.1, 2025 (SCI-Expanded, Scopus)

8. Efficacy of Palbociclib and Ribociclib in Second-line Treatment of Metastatic Hormone Receptor-positive Breast Cancer: A Single-center Experience

Yildirim S., SEVER Ö. N., Akdaĝ Topal G., Orman S., Aydoĝan M., Türkoĝlu E., et al.

Journal of Oncological Science , cilt.11, sa.3, ss.224-232, 2025 (Scopus, TRDizin)

9. The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis

Yıldırım S., Başoğlu T., Doğan A., Akdağ G., Kınıkoğlu O., Topal A., et al.

BMC Cancer , cilt.25, sa.1, 2025 (SCI-Expanded, Scopus)

10. Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage

Basoglu T., Ozkerim U., Oksuz S., Kinikoglu O., Yildirim S., Kokten S., et al.

Journal of Clinical Medicine , cilt.14, sa.19, 2025 (SCI-Expanded, Scopus)

11. Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

Bolek H., Kuzu O. F., Sertesen Camoz E., Sim S., Sekmek S., Karakas H., et al.

Clinical and Translational Oncology , cilt.27, sa.7, ss.3110-3120, 2025 (SCI-Expanded, Scopus)

12. The impact of smoking on nivolumab outcomes in renal cell carcinoma: Real-world data from the Turkish Oncology Group Kidney Cancer Consortium

Sertesen Camoz E., Bolek H., Kuzu O. F., Sim S., Karakaş H., Sekmek S., et al.

Oncologist , cilt.30, sa.7, 2025 (SCI-Expanded, Scopus)

13. Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

Bolek H., Kuzu O. F., Sertesen Camoz E., Sim S., Sekmek S., Karakas H., et al.

Cancer Communications , cilt.45, sa.5, ss.572-576, 2025 (SCI-Expanded, Scopus)

14. Relationship of Tumor Localization and Lipid Parameters with Survival in Patients with Colorectal Cancer

SEVER Ö. N., Başoğlu T., Yıldırım S.

Journal of Clinical Medicine , cilt.14, sa.4, 2025 (SCI-Expanded, Scopus)

15. Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

Bölek H., Sertesen E., Kuzu O. F., Tural D., Sim S., Nahit Şendur M. A., et al.

Clinical Genitourinary Cancer , cilt.23, sa.1, 2025 (SCI-Expanded, Scopus)

16. Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium

AYKAN M. B., Bölek H., YEKEDÜZ E., Sertesen E., Tural D., Karaçin C., et al.

Therapeutic Advances in Medical Oncology , cilt.17, 2025 (SCI-Expanded, Scopus)

17. Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

Sekmek S., Bolek H., Kuzu O. F., Camoz E. S., Sim S., Karakaş H., et al.

Immunotherapy , cilt.17, sa.9, ss.649-655, 2025 (SCI-Expanded, Scopus)

18. The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

Yildirim S., Dogan A., Akdag G., Yüksel Yasar Z., Bal H., Kinikoglu O., et al.

Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded, Scopus)

19. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

Isik D., ALAN Ö., Akdağ G., Yildirim S., Kınıkoğlu O., Altintas Y. E., et al.

Journal of Clinical Medicine , cilt.13, sa.20, 2024 (SCI-Expanded, Scopus)

20. Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis

Yildirim S., ALAN Ö., Yuksel Yasar Z., KAYA T., Akdag G., Kinikoglu O., et al.

Medicina (Lithuania) , cilt.60, sa.8, 2024 (SCI-Expanded, Scopus)

21. A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

Yildirim S., Dogan A., Akdag G., Cavdar E., Kinikoglu O., Oksuz S., et al.

Cancers , cilt.16, sa.14, 2024 (SCI-Expanded, Scopus)

22. The Effectiveness of Adjuvant PD-1 Inhibitors in Patients with Surgically Resected Stage III/IV Acral Melanoma

Arak H., Erkiliç S., Yaslikaya Ş., Eylemer Mocan E., Aktaş G., Özdemir M., et al.

Journal of Immunotherapy , cilt.47, sa.5, ss.182-189, 2024 (SCI-Expanded, Scopus)

23. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status

Akdag G., Yildirim S., Dogan A., Yasar Z. Y., Bal H., Kinikoglu O., et al.

Chemotherapy , cilt.69, sa.3, ss.141-149, 2024 (SCI-Expanded, Scopus)

24. Prognostic scores in pulmonary large cell neuroendocrine carcinoma: A retrospective cohort study

Akdag G., ALAN Ö., Dogan A., Yildirim S., Kinikoglu O., Batu A., et al.

Heliyon , cilt.10, sa.3, 2024 (SCI-Expanded, Scopus)

25. Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium

Erol C., YEKEDÜZ E., Tural D., KARAKAYA S., Şentürk Öztaş N., Uçar G., et al.

Urologia Internationalis , cilt.107, sa.6, ss.595-601, 2023 (SCI-Expanded, Scopus)

26. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

YEKEDÜZ E., KARAKAYA S., ERTÜRK İ., Tural D., Uçar G., Şentürk Öztaş N., et al.

Clinical Genitourinary Cancer , cilt.21, sa.1, ss.175-182, 2023 (SCI-Expanded, Scopus)

27. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

YEKEDÜZ E., Tural D., ERTÜRK İ., KARAKAYA S., Erol C., Ercelep Ö., et al.

Journal of Cancer Research and Clinical Oncology , cilt.148, sa.12, ss.3537-3546, 2022 (SCI-Expanded, Scopus)

28. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors

Yücel K. B., YEKEDÜZ E., KARAKAYA S., Tural D., ERTÜRK İ., Erol C., et al.

Scientific Reports , cilt.12, sa.1, 2022 (SCI-Expanded, Scopus)

29. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database

YEKEDÜZ E., ERTÜRK İ., Tural D., KARADURMUŞ N., KARAKAYA S., Hlzal M., et al.

Future Oncology , cilt.17, sa.35, ss.4861-4869, 2021 (SCI-Expanded, Scopus)